A stable 15-amino acid peptide derived from human gastric juice, widely investigated for tissue healing, angiogenesis, and gut mucosa integrity.
~4 hours
VEGFR2
C62H98N16O22
Investigated via subcutaneous injection, localized intramuscular administration, and oral delivery (as stable arginate salt).
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for BPC-157: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C62H98N16O22
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
BPC-157 (Body Protection Compound-157) represents a partial sequence of the endogenous gastric protein BPC. Preclinical investigations show marked resilience to gastric acid and digestive enzymes. Extensive animal models illustrate accelerated repair across transected tendons, crushed nerves, bone non-unions, and inflammatory bowel disease models.
Promotes vascular endothelial growth factor (VEGF) receptor activation (VEGFR2), accelerates FAK-paxillin pathway phosphorylation in fibroblasts, and regulates nitric oxide (NO) synthase dynamics.
Peer-reviewed publications, clinical trials, and preclinical research investigating BPC-157.
Preclinical biomechanical assessment showing accelerated structural restoration, functional load tolerance, and enhanced VEGFR2 phosphorylation following BPC 157 administration.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Daily or twice daily
“Calculated based on 5-10 mcg/kg extrapolations in published animal gastrointestinal and orthopedic repair models.”
Biological delivery routes and standardized laboratory reconstitution principles.
Investigated via subcutaneous injection, localized intramuscular administration, and oral delivery (as stable arginate salt).
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolGlobal scientific standards organizations publish technical guidelines on reconstitution temperature, secondary protein structure preservation, and solvent selection.
Read ArticleMaster the underlying biology, pharmacokinetics, and reconstitution protocols relevant to BPC-157.
The essential guide to reconstitution mathematics, understanding microgram to milligram relationships, and converting syringe unit markings accurately.
A critical guide to scientific literacy: why impressive rodent and cell-culture results cannot be equated to proven human clinical efficacy.
The physical chemistry of peptide storage: understanding why temperature fluctuations, UV light, and mechanical agitation degrade fragile amino acid chains.
Compiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
